PF614-MPAR — Full data
late Q4 2026
A second study, PF614-MPAR-102, designed to evaluate the overdose protection across a range of dosages, initiated enrollment of subjects in December 2024 and has completed enrollment, with final data expected in late Q4 2026.Source filing